Humana (HUM) Q1 2026 earnings review
Massive Growth Masks a Severe Earnings Reset
Humana's 23% YoY revenue surge looks impressive on the surface, driven by an accelerating influx of 1.1 million new Individual Medicare Advantage (MA) members in Q1. However, this volume is not reaching the bottom line. A brutal ~$3.5 billion Star Ratings headwind is compressing margins, pushing the core Individual MA business slightly below breakeven for the year. Even the CenterWell segment, expected to benefit from MA synergies, saw its operating income reverse and fall 26% YoY due to acquisition integration and risk-model phase-ins. While management defends the massive membership influx as 'good growth' that will unlock long-term value by 2028, investors face a painful transition year with FY26 Adjusted EPS guided to nearly half of FY25 levels.
🐂 Bull Case
Accelerating Individual MA growth (+22% YTD) is bringing in over a million new members. Management notes 70% of new sales were switchers and 75% came from high lifetime-value channels, setting the stage for significant out-year profitability once the Star Ratings penalty lapses.
CenterWell Senior Primary Care added 110,500 patients (+22% sequentially), bolstered by the MaxHealth acquisition. The integration of a rapidly expanding captive MA member base creates a structural advantage for future care-delivery monetization.
🐻 Bear Case
FY26 Adjusted EPS guidance of 'at least $9.00' represents a nearly 50% drop from FY25's $17.14. First-quarter EPS of $10.31 implies severe expected losses in the second half of the year due to structural IRA changes and Star Ratings penalties.
Despite management touting enterprise synergies, CenterWell's operating income fell 26% YoY to $289M, and its operating cost ratio spiked to 94.5%. Volume is growing, but profitability is reversing.
⚖️ Verdict: 🔴
Bearish. Top-line acceleration is impressive, but the cost of that growth—combined with the unavoidable $3.5B Star Ratings headwind—means the core insurance business is operating near breakeven. Management's 2028 turnaround vision requires flawless execution over the next 24 months.
Key Themes
Explosive Individual MA Growth
Accelerating volume is the headline story. Humana added 1.14 million Individual MA members in Q1 (a 22% increase). Management vehemently defended this as 'good growth,' noting that 30% were 'bounce-back' members returning to Humana, and the company only absorbed 12% of members from competitor plan exits—meaning they aren't just catching adverse-selection fallout. This scale gives Humana a massive base to harvest if they can fix their Star Ratings.
CenterWell Profitability Squeeze Contradicts Synergy Narrative
Reversing profitability in the healthcare services arm is a major red flag. Management cited the MA membership influx as a 'significant tailwind' for CenterWell. However, CenterWell's Q1 operating income dropped to $289 million (down from $392 million in 1Q25), and its operating cost ratio jumped 340 basis points to 94.5%. Management blamed the final year of the v28 risk model phase-in, specialty pharmacy volume mix, and MaxHealth integration costs. If CenterWell can't leverage massive captive volume into immediate profit, the integrated model's near-term value is questionable.
The $3.5 Billion Star Ratings Hangover
Stable but severe. The highly anticipated Bonus Year 2026 Star Ratings headwind is finally hitting the P&L, quantified at a massive ~$3.5 billion. Because the MA membership base grew faster than expected, the absolute dollar penalty is actually larger than prior estimates. This penalty is the singular reason the Individual MA pretax margin is guided to be 'slightly below breakeven' for the year.
Macro Pressure: Final MA Rate Notice Gap
Decelerating government support remains a headwind. Management acknowledged that the Final MA Rate Notice for 2027 shows a persistent gap versus actual medical cost trends. Humana signaled they will adapt benefits to ensure they return to a stable margin, which implicitly risks future membership retention if benefits are cut aggressively.
Agentic AI and Tactical Transformation
Accelerating cost controls are helping offset top-line pressure. The consolidated operating cost ratio improved 50 basis points to 10.0% (Adjusted). Beyond raw operating leverage from membership growth, management highlighted the deployment of 'agentic AI platforms' in contact centers to streamline operations, alongside earlier tactical moves like outsourcing finance to Genpact and optimizing supplier consolidation.
Other KPIs
Stable sequentially but down significantly YoY (from 38.8 days in 1Q25). The YoY drop is primarily due to an increased proportion of Medicare prescription drug benefit expense tied to the Inflation Reduction Act (IRA). Pharmacy claims process faster than medical claims, naturally pulling down DCP. Management indicates IBNR balances actually increased 35% sequentially to match membership growth, suggesting reserves remain adequate.
Accelerating leverage. Rose 190 basis points from 41.1% at the end of 2025. This was driven by a $1.0 billion Junior Subordinated Notes offering in March. While slightly above their ~40% long-term target, management notes this specific rating-agency-friendly instrument attracts equity credit and helps offset the $3.2 billion in capital contribution requirements for 2026 driven by the massive membership growth.
Accelerating. Up sharply from $331 million in 1Q25. The surge is driven by favorable working capital dynamics, specifically the massive sequential increase in incurred but not reported (IBNR) claims balances tied to the 22% jump in new Medicare Advantage members.
Guidance
Decelerating drastically from FY25's $17.14. Notably, Q1 2026 already delivered $10.31 in Adjusted EPS, and management expects Q2 to deliver 80-85% of the full-year target ($7.20+). This implies catastrophic losses in the second half of 2026 as the IRA seasonality and Star Ratings headwinds fully materialize.
Decelerating. Revised downward from prior guidance of 'at least $8.89'. The downward revision is linked to complex put/call valuation adjustments tied to minority interest investments, rather than underlying medical cost deterioration.
Accelerating. Reaffirmed guidance. With 1.14 million members already added in Q1, Humana has effectively achieved the bulk of this target. The focus now shifts purely to retaining these members and managing their initial, higher-cost medical loss ratios.
Deteriorating (higher is worse). Reaffirmed. Q1 came in at 89.4%, which means the remaining quarters will run significantly hotter than 92.75% to average out to the annual guidance, underscoring the severe back-half seasonality.
Key Questions
New vs. Retained Member Margins
You noted that Individual MA margins will be slightly below breakeven in 2026. Given the massive influx of 1.1 million new members, what is the exact margin differential between your retained book (bearing the brunt of the Stars penalty) and this new 2026 cohort bearing higher initial acquisition and care-management costs?
CenterWell Margin Recovery
CenterWell's operating cost ratio spiked to 94.5% despite a 22% sequential increase in primary care patients. How much of this 340 bps YoY margin deterioration is structural from the final v28 phase-in, versus one-time integration costs for MaxHealth, and when will margins inflect positively?
H2 2026 Seasonality Cliff
With Q1 delivering $10.31 in Adj EPS and Q2 expected to deliver ~80% of the $9.00 full-year target, you are implying massive losses in H2. What specific levers are you pulling to ensure this back-half pressure doesn't bleed into the 2027 pricing baseline?